Close button
Enquiry IconContact Us
Logo

DNA Repair Drugs Market – Breakthrough for Cancer Patients

DNA repair drugs are used in repairing damaged DNA and for treating cancers. DNA damage results in genetic disorders, however the human body has its own mechanisms to correct the DNA sequence. DNA repair drugs such as PARP inhibitors and other DNA repair drugs help to treat diseases with genetic aberrations.

The global DNA repair drugs market size was valued at US$ 461.3 Mn in 2017, and is expected to exhibit a CAGR of 32.4% over the forecast period (2018–2026).

Figure 1. Global DNA Repair Drugs Market Value (US$ Mn), by Region, 2018

DNA Repair Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Increasing incidence of cancer, rising government initiatives to promote awareness for cancer treatment, and expansion strategies by manufacturers to increase and expand their product portfolio in the international markets are factors propelling growth of the global DNA repair drugs market

Increasing incidence of cancer is expected to drive the global DNA repair drugs market growth over the forecast period. According to the World Cancer Research Fund International’s report in 2018, breast cancer accounted for the second highest number of cancer cases (2,088,849 new cases) across the globe in 2018. According to GLOBOCAN, 43.6% new cases of breast cancer were registered in Asia Pacific in 2018.

Moreover, increasing drug approval by key players in order to address demand for efficient therapeutics, is expected to propel growth of the market over the forecast period. In October 2018, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for Talazoparib (Talzenna) for treating patients with HER2 (negative locally advanced or metastatic breast cancer).

However, Delays in regulatory approvals lead to delay in marketing of the product, which can adversely affect the revenue generation of the manufacturer. Similarly, delay in post approval of the drug product for other therapeutic indication results in increasing clinical trials costs and can impact the labelling and approval status of currently marketed products.

Figure 2. Global DNA Repair Drugs Market Share (%), by Drug Type, (2018-2026)

DNA Repair Drugs  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Rising prevalence of cancer, as well as increasing collaborations and acquisitions by key players is expected to boost the market growth

North America is expected to dominate the global DNA repair drugs market over the forecast period owing to increasing incidence of cancer. According to the American Cancer Society, in 2018, an estimated 266,120 new cases of invasive breast cancer were diagnosed in the U.S. Moreover, increasing demand for cancer treatments is expected to drive growth of the DNA repair drugs market in the region.

Market players are engaged in research and development activities in order to meet the rising demand DNA repair drugs. In May 2019, Clovis Oncology, Inc., collaborated with Bristol-Myers Squibb Company and Foundation Medicine Inc. to initiate phase II study for evaluating rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometroid ovarian cancer.

Key Players

Major players operating in the global DNA repair drugs market are AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.

FAQ

Frequently Asked Questions

The global DNA repair drugs market is estimated to surpass US$ 8,378.1 Million by 2026.
Major players operating in the global DNA repair drugs market include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
Delays in regulatory approvals lead to delay in marketing of the product and this is one of the major factors that is expected to hamper growth of the market over the forecast period.
Increasing incidence of canceris one of the major factors that is expected to propel growth of the market over the forecast period.
The global DNA repair drugs market is estimated to exhibit a CAGR of 32.4% over the forecast period.
Among regions, North Americais expected to hold dominant position in the DNA repair drugs market over the forecast period.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.